A cost-effectiveness analysis of screening strategies for cervical intraepithelial neoplasia

Journal of Lower Genital Tract Disease

Volumn 8, Issue 4, 2004, Pages 280-284

  Straughn Jr , J Michael ^a   Numnum, T Michael ^a   Rocconi, Rodney P ^a   Leath III, Charles A ^a   Partridge, Edward E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cervical intraepithelial neoplasia; Cost effectiveness analysis; Liquid based cytology

Indexed keywords

ARTICLE; CANCER SCREENING; COLPOSCOPY; COST; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; PAPANICOLAOU TEST; REIMBURSEMENT; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

EID: 4944252139     PISSN: 10892591     EISSN: None     Source Type: Journal    
DOI: 10.1097/00128360-200410000-00004     Document Type: Article

References (12)

1. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda system-terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
2. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-62.
3. American College of Obstetrics and Gynecology. Cervical cytology screening. ACOG Practice Bulletin No. 45. Obstet Gynecol 2003;102:417-27.
4. Wright TC, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287: 2120-9.
5. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-9.
6. Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001;285:3107-15.
7. Sawaya GF, McConnell KJ, Kulasingam SL, Lawson HW, Kerlikowske K, Melnikow J, et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screening. N Engl J Med 2003;349:1501-9.
8. Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang Y, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002;287: 2372-81.
9. Wright TC, Schiffman M, Soloman D, Cox JT, Garcia F, Goldie S, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004;103:304-9.
10. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004; 103:619-31.
11. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities. JAMA 2003;288:1749-57.
12. Myers ER, McCrory DC, Subramanian S, McCall N, Nanda K, Datta S, et al. Setting the target for a better cervical screening test: characteristics of a cost-effective test for cervical neoplasia screening. Obstet Gynecol 2002;96:645-52.